GE HealthCare's MINItrace™ Magni achieves CE Mark; Copper-64 expands PETtrace™ Solid Target Platform beyond Gallium-68

Erez Levy, Vice President of Molecular Imaging at GE HealthCare

“The molecular imaging landscape is being reshaped by the expansion of theranostics, the introduction of new PET tracers, and demand across oncology, neurology and cardiology”

Erez Levy, Vice President of Molecular Imaging at GE HealthCare

“As tracer portfolios broaden, healthcare providers need reliable access to radioisotopes and the flexibility to respond to changing clinical needs. That calls for a longer-term view of radiopharmaceutical production—one that supports established services while allowing institutions to prepare for new clinical and research applications.”

Nicolas Durand-Schaefer, General Manager, Molecular Imaging, International, GE HealthCare

“A molecular imaging program needs a plan for the tracers it uses today and the ones it may want to explore tomorrow”

Nicolas Durand-Schaefer, General Manager, Molecular Imaging, International, GE HealthCare

“MINItrace Magni’s CE Mark is an important milestone for a compact, versatile cyclotron designed to support local radioisotope production and enable healthcare providers to build radiopharmacy capabilities without the need for large-scale production infrastructure. Adding Copper-64 to PETtrace broadens the platform’s capabilities to support copper-based imaging and theranostics research. Our focus is on helping institutions connect the practical demands of running a radiopharmacy with their longer-term clinical and research ambitions.”